Advanced T-cell non-Hodgkin's lymphoma in adults has been found to have a poor outlook with conventional chemotherapy. To see if this extends to patients treated with high dose therapy and autologous hematopoietic stem cell transplantation, we reviewed the results with this treatment approach at our institution. From October, 1983, to May, 1988, 41 patients who underwent high-dose therapy and autologous hematopoietic stem cell transplant for recurrent non-Hodgkin's lymphoma were re-biopsied before transplantation to determine their immunophenotype. Seventeen of these patients were found to have a T-cell lymphoma, and 24 had a 6-cell lymphoma. 0006-4971/90/7602-0018$3.00/0 logically transformed from a low grade lymphoma. Analysis of the response to autologous transplantation in these two patient populations revealed a slightly better complete response rate for patients with T-cell lymphoma (ie, 59% versus 42%. P = NS). The actuarial 2-year survival was 35% in the T-cell group compared with 30% in the B-cell group ( P = NS). The 2-year disease-free survival was 28% for the T-cell and 17% for the B-cell patients. Our results with autologous transplantation for salvage therapy revealed equivalent long-term survival and disease-free survival in both relapsed T-and B-cell non-Hodgkin's lymphoma.
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All pathologic materials were reviewed and classified according to the Working Formulation for Uniform Classification of NHL.2' Seventeen patients had a T-cell lymphoma, and 24 patients had a B-cell lymphoma. Twenty-four patients had frozen biopsy tissue available at the University of Nebraska Medical Center for immunophenotyping using the following protocol. A portion of the patient's specimen had been snap frozen in Optimum Cutting Temperature Compound (OCT, Ames, Naperville, IL) by immersing the specimen in liquid nitrogen or a slurry of N-methyl-butanol and dry ice. The tissue was then stored in air-tight bags at -7OOC and was stained with a panel of monoclonal T-and B-cell markers within 48 hours. Cryostat sections (6 p thick) were cut and placed on albumin-coated slides. Sections were warmed to room temperature and fixed in acetone for 5 minutes. After washing with phosphatebuffered saline (PBS; 0.1 mol/L, pH 7.4), the sections were incubated with selected monoclonal antibodies or with polyvalent rabbit antibodies. After washing three times in PBS, bound antibody was demonstrated by an avidin-biotin immunohistochemical procedure (Vectastin; Vector Laboratories, Burlingame, CA). The monoclonal antibodies (MoAbs) used in this study were as follows: B1, B2, and B4 (Coulter Immunology, Hialeah, FL); BAl, BA2 (Hybritech, San Diego, CA); Leu-1, Leu-2, Leu-3, Leu-4, Leu-14, antiinterleukin-2 receptor (IL-ZR), and anti-HLA-DR (BectonDickinson, Sunnyvale, CA); OKT4, OKT8, OKT9, and OKTll (Ortho Pharmaceuticals, Raritan, NJ); anti-Kappa and antiLambda mouse MoAb (Chappel Laboratory, Cochranville, PA); anti-Kappa, anti-Lambda, and anti-IgG, IgA, IgM, and IgD (Dako, Santa Barbara, CA).
Nine patients had formalin-fixed paraffin-embedded tissues examined at the University of Nebraska Medical Center. They were stained by MoAbs UCHL and L26 (DAKO, Santa Barbara, CA), which mark specifically for T cells and B cells, respectively. Two additional patients had their immunophenotyping confirmed by flow cytometry at our institution. The remaining six patients had immunophenotyping done at their referring institutions by flow cytometry (n = 2), frozen sample analysis (n = 3), or analysis of touch
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preparations of a lymph node biopsy by immunostaining for lambda immunoglobulin light chain and pan B-cell marker Leu-14 (n = 1). Cases were identified as being of either B-or T-cell type when the vast majority of cells stained with one or more lineage-specific antibodies or the flow cytometry demonstrated the majority of cells to be lineage-specific.
Patients were evaluated before transplantation with procedures including history and physical examination, chest radiography, abdominal computed tomography, complete blood count, chemistry profile, bone marrow biopsy, and gallium scan as indicated. The patients ranged in age from 15 to 57 years (median, 33) in the T-cell NHL group and from 15 to 59 years (median, 39) in the B-cell NHL group. The male to female ratio in the T-cell NHL group was 9:8 compared with 14:lO in the B-cell NHL group. Further patient characteristics are outlined in Table 1 .
These patients were treated on several consecutive studies of preparative regimens during the time period covered by this report. A few patients were unable to receive total body irradiation because of previous radiation given as part of their initial therapy and, therefore, received preparative regimens containing chemotherapy only. Eight patients (four B-cell, four T-cell) received melphalan, 70 mg/mz on days 1 and 2 and total body irradiation (TBI), 180 cGy twice daily for five doses22; 11 patients (seven B-cell, four T-cell) received cyclophosphamide, 90 mg/kg on day 1, cytarabine 3 gm/m2 every 12 hours on days 1 through 3, and TBI 250 cGy daily for 5 days"; seven patients (four B-cell, three T-cell) received cyclophosphamide 1.5 g/mZ on days 1 through 4, etoposide 150 mg/m2 every 12 hours on days 1 through 3, and carmustine 300 mg/m2 on day 1.24 Four patients (three B-cell, one T-cell) received cyclophosphamide 60 mg/kg on days 1 and 2 and TBI 200 cGy twice daily for six doses25; nine patients (four B-cell, five T-cell) received 2,600 cGy local radiotherapy to bulky sites of disease followed by cyclophosphamide 35 mg/kg on days 1 through 4, cytarabine 100 mg/mz every 12 hours on days 1 through 4, etoposide 100 mg/m2 every 12 hours on days 1 through 4, and Treatment regimens. Table 1 carmustine 300 mg/m2 on day 126; two patients (both B-cell) received cyclophosphamide 2.5 g/mZ every 12 hours on days 1 and 2, etoposide 150 mg/m2 every 12 hours on days 4 through 6, BCNU 300 mg/m2 on day 1, and hydroxyurea 1.5 g/m2 orally every 6 hours on days 4 through 6.27 Thirty-seven patients received cryopreserved autologous bone marrow, and four patients received cryopreserved peripheral stem cells (three B-cell and one T-cell patient) as described by Kessinger et alZ8 for their hematopoietic rescue product.
Of the patients receiving cryopreserved peripheral stem cells, two of the B-cell patients and the T-cell patient had a bone marrow that was involved with lymphoma at the time of transplantation. One of the B-cell patients had a previously positive bone marrow for lymphoma, although at the time of transplant the bone marrow was not involved. Complete response (CR) was defined as the complete disappearance of all clinical evidence of disease with normalization of all laboratory, physical examination, and radiographic abnormalities that were present before autologous hematopoietic stem cell transplant. A partial response (PR) was defined as a reduction of 50% in diameter in two dimensions from the original size of all measurable lesions for at least 1 month. No response (NR) was defined as less than a PR, and an early death (ED) was defined as any patient dying while still hospitalized for their transplant and, therefore, inevaluable for response of their disease to transplantation. Duration of response was measured from the time of documentation of CR after ABMT until evidence of recurrent disease.
Survival of the groups was calculated using the life table method.z9
Statistical significance was determined using the x2 test with Yates correction as appropriate when comparing the frequency of an occurrence between groups. The significance of difference between survival curves was determined using the log rank test.
Response criteria and statistics.
RESULTS
Of the 41 patients, 17 (41%) had T-cell NHL by immunophenotyping, and the remaining 24 (59%) had B-cell NHL. The details of the 17 T-cell lymphoma patients are presented in Table 2 . There was no significant difference between the T-cell and B-cell patients with respect to age distribution, male to female ratio, performance status, stage at presentation, lactic dehydrogenase level, or tumor bulk. The histologic subtypes were distributed throughout the intermediate and high grade classifications (Table 1) . Of the T-cell patients, two were resistant to chemotherapy administration immediately before the transplant, four were sensitive to pretransplant chemotherapy, and 11 were not tested. The B-cell patients had two patients with resitant relapse, six patients had a sensitive relapse, and 16 were not tested.
The patients with T-cell NHL had a slightly higher complete remission rate with transplantation-59% compared to 42%-al t hough this difference was not statistically significant (P = NS) ( Table 3 ). The complete remission durability was identical in both B-and T-cell patients: 50% at 30 months with no later relapses (Fig 1) . The therapyrelated mortality among the 41 patients was also similar in the two categories. The T-cell group suffered three toxic early deaths (1 8%), as compared with five (21 %) in the B-cell group (Table 3 ). The toxic treatment-related deaths were due to renal failure (n = l ) , diffuse alveolar hemorrhage (n = 2), or bacterial and fungal sepsis (n = 5).
The overall survival for the B-and T-cell patients was similar. T h e median follow-up of surviving patients is 28 months (range, 20 to 58 months). T h e actuarial 2-year 
2.
3. 1. survival of the T-cell patients was 35% compared with 30% for the B-cell patients (Fig 2) . The actuarial disease free survival of the T-cell patients was 28% compared with 17%
for the B-cell patients (Fig 3) . In the B-cell N H L group, all eight patients with a partial or no response to therapy have died of progressive disease from 2 to 6 months posttransplant. One patient died while in complete remission at 22 months posttransplant of complications due to a myelodysplastic syndrome with the 5q -chromosomal abnormality. Five patients have relapsed from a complete response from 4 to 24 months after autologous transplant. Three of those relapsed patients are still alive with disease at 23, 24, and 26 months posttransplant. Four patients are currently alive in initial complete remission after following autologous hematopoietic stem cell transplant from 20 to 58 months posttransplant (Fig 1) .
Of the patients with T-cell NHL, the four patients with a partial or no response to therapy have died of progressive disease from 5 to 21 months after transplant. Four patients relapsed from complete remission and died of recurrent disease from 1 1 to 13 months after transplant. Another patient relapsed at 30 months posttransplant but is currently alive in remission after further therapy at 53 months after the transplant. Five patients remain alive in complete remission from 21 to 48 months after transplant.
Three factors at the time of ABMT were powerful predictors of a poor outcome with high-dose therapy and autologous transplantation in both B-and T-cell patients. All patients with a poor performance status (570 Karnofsky score; n = 8), bulky tumor (greater than 10 cm mass; (Fig 4) . Immnophenotype was not predictive of transplant outcome, with equivalent survival in both B-and T-cell groups.
DISCUSSION
High-dose therapy and autologous hematopoietic rescue using bone or peripheral stem cells" has been documented to be an effective modality in the treatment of some patients with relapsed NHL. Several prognostic factors have now been identified as predictive of a poor outcome with transplantation, such as tumor performance status,22 and chemotherapy-resistant disease." While the role of immunophenotyping has been extensively examined in the N H L patient receiving front-line chemotherapy, there have been few series studying its prognostic significancce in the setting of high-dose therapy and autologous hematopoietic stem cell transplant.
Our study evaluated 41 patients who were undergoing high-dose therapy and autologous hematopoietic transplant for relapsed NHL. Twenty-four of these patients had B-cell NHL, while 17 exhibited T-cell immunophenotype. The evaluable patients were similar as far as patient characteristics and histologic subtype. With respect to complete response rate and overall survival after high-dose chemo/ radiotherapy with autologous bone marrow or peripheral stem cell transplantation, there was no significant difference found between the B-and T-cell patient groups.
It has been the impression of many oncologists that T-cell N H L patients have a worse prognosis than B-cell N H L patients with respect to disease-free survival after front-line chemotherapy. Although not all studies have found immunophenotyping to be of good predictive value in this setting, many series have found this to be a strong predictor of patient outcome. months, compared with 18 months for the T-cell patients. Other studies have identified specific subgroups, such as stage IV T-cell patients, with particularly poor outcome: 0 to 10% 4-year disease-free ~urvival.'~.'~ One study identified the immature T phenotype as another subclassification of T-cell patients that did poorly with front-line chemotherapy as described by Coiffier et a1.I6 With many T-cell N H L patients responding poorly to front-line chemotherapy, high-dose chemofradiotherapy followed by autologous hematopoietic rescue is being done as salvage therapy with increased frequency in this patient population.
Our study shows that T-cell patients do at least as well as comparable B-cell N H L patients under the conditions of dose escalation and hematopoietic rescue. The reasons for improved response of T-cell N H L patients to high-dose
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Months post ABMT chemo/radiotherapy and autologous transplant as compared with their response to front-line aggressive therapy is not clear at this time. This may reflect a greater sensitivitiy in these tumors to the dose escalation used in transplantation as compared with conventional chemotherapy doses. Further evaluation may help to answer this question.
As convincing data emerges to demonstrate that T-cell NHL patients, especially those with stage IV disease, respond poorly to initial therapy, consideration should be given early on use of high-dose therapy and autologous bone marrow or peripheral stem cell transplantation. Trials using autologous transplantation in first partial or early complete remission in high-risk T-cell patients are ongoing and should add additional information to our knowledge regarding the best treatment plan for this patient group.
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